Regenesis

Company Overview

Snapshot

Founded in February 2023, Regenesis operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its innovative mESh Technology platform for cartilage regeneration.

Business overview

Regenesis is a biomedical startup focused on revolutionizing the treatment of cartilage lesions. The company's core technology is a unique biocompatible structure designed for in situ enhancement of cartilage regeneration through a minimally invasive procedure. This platform aims to enable full restoration of cartilage and can be adapted for various medical conditions associated with cartilage damage, including hip and ankle lesions and Osteoarthritis (OA). Regenesis operates within the Health Tech & Life Sciences sector, specifically targeting Biomaterials & Tissue Engineering within Pharma & Medical Biotechnology, and serves the Healthcare market.

Company Intelligence Q&A

What is Regenesis' primary focus?

Regenesis is a biomedical startup focused on cartilage regeneration through electrical stimulations, aiming to revolutionize the treatment of cartilage lesions.

When was Regenesis founded?

Regenesis was founded in February 2023.

What is the core technology developed by Regenesis?

Regenesis is developing the mESh Technology platform, which is based on a unique biocompatible structure designed for direct or indirect application to damaged cartilage areas.

Which medical conditions does Regenesis aim to address?

Regenesis' platform can be adopted for tissue regeneration in various medical conditions associated with cartilage damage, including hip and ankle lesions and Osteoarthritis (OA).

What is the current product stage of Regenesis' technology?

Regenesis' product, the mESh Technology platform, is currently in the R&D stage.